Identifying new mechanisms of action is vital for pre-clinical and clinical trials.

Transcription inhibitors

  • Trabectedin and lurbinectedin
    Trabectedin and Lurbinectedin are two selective inhibitors of trans-activated RNA polymerase II transcription. They selectively block the elongation phase of messenger RNA synthesis performed by RNA polymerase II. They do not inhibit RNA polymerase I or mitochondrial RNA polymerase, nor do they affect basal transcription: their action mechanism very selectively inhibits RNA polymerase II transcription. This is reflected in clinical results, since some tumors present transcriptional addiction (e.g. translocation-related sarcomas, small cell lung cancer, and triple negative breast cancer). These are clear examples of tumors that are sensitive to lurbinectidin.

eEF1A2 inhibitors

  • Plitidepsin
    Another of our drugs specifically inhibits a protein called eEF1A2. Inhibiting this cell target induces higher oxidative stress in tumor cells and triggers enzymes that accelerate cell death.

Tubulin inhibitors

  • PM184
    This compound inhibits tubulin polymerization. These proteins form part of the cell’s skeleton (the cytoskeleton). As a result, the cytoskeleton becomes degraded and the tumor cells lose the capacity to mobilize and divide.

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs.

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.


If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom